281 related articles for article (PubMed ID: 29315497)
21. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
[TBL] [Abstract][Full Text] [Related]
22. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
23. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
25. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
26. Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non-Small Cell Lung Cancer Are Associated With Decreases in Overall Survival.
Deek MP; Kim S; Beck R; Yegya-Raman N; Langenfeld J; Malhotra J; Mahmoud O; Aisner J; Jabbour SK
Clin Lung Cancer; 2018 Jul; 19(4):e381-e390. PubMed ID: 29752011
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Vyfhuis MAL; Bhooshan N; Molitoris J; Bentzen SM; Feliciano J; Edelman M; Burrows WM; Nichols EM; Suntharalingam M; Donahue J; Nagib M; Carr SR; Friedberg J; Badiyan S; Simone CB; Feigenberg SJ; Mohindra P
Lung Cancer; 2017 Dec; 114():44-49. PubMed ID: 29173764
[TBL] [Abstract][Full Text] [Related]
28. Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities.
Bilfinger T; Keresztes R; Albano D; Nemesure B
Med Sci Monit; 2016 Jul; 22():2589-94. PubMed ID: 27442604
[TBL] [Abstract][Full Text] [Related]
29. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
[TBL] [Abstract][Full Text] [Related]
30. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.
Lester-Coll NH; Park HS; Rutter CE; Corso CD; Young MR; Ratner ES; Litkouhi B; Decker RH; Yu JB; Damast S
Gynecol Oncol; 2016 Jul; 142(1):54-61. PubMed ID: 27151429
[TBL] [Abstract][Full Text] [Related]
31. Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016.
Shah M; Parmar A; Chan KKW
Cancer Med; 2020 May; 9(10):3407-3416. PubMed ID: 32196964
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
[TBL] [Abstract][Full Text] [Related]
33. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy.
Zhou R; Xu T; Nguyen QN; Liu Y; Yang J; Komaki R; Gomez DR; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):452-461. PubMed ID: 29174428
[TBL] [Abstract][Full Text] [Related]
34. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
[TBL] [Abstract][Full Text] [Related]
35. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non-Small-Cell Lung Cancer.
Wang EH; Rutter CE; Corso CD; Decker RH; Wilson LD; Kim AW; Yu JB; Park HS
J Thorac Oncol; 2015 Jun; 10(6):937-43. PubMed ID: 25738221
[TBL] [Abstract][Full Text] [Related]
36. The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy.
Koshy M; Malik R; Sher DJ; Spiotto M; Mahmood U; Aydogan B; Weichselbaum RR
Clin Lung Cancer; 2014 Sep; 15(5):365-71. PubMed ID: 24984565
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
38. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
39. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
40. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
